Therefore, the insertion of the anti-PD-L1 scFv in the construct can lead not only to the higher binding ability of the tri-specific antibody to tumor cells but can also significantly potentiate the activation of T cells and consequent tumor cell killing by efficiently interfering with the increased PD-L1-PD-1 interaction. Here, PDCD1 is linked to neoplasm.